Mandate

Vinge advises Isofol in connection with its listing on Nasdaq Stockholm

Vinge has advised Isofol Medical AB in connection with its listing on Nasdaq Stockholm, with the first day of trading on 21 October 2021. The prospectus was approved by the Swedish Financial Supervisory Authority on 18 October 2021. Isofol has a market value corresponding to approximately SEK 1.5 billion.

Isofol is a biotech company in late clinical phase which develops arfolitixorin in order to improve standard treatment of 5-FE based chemotherapy, primarily for advanced colorectal cancer, by increasing tumour response and progression free survival.

Vinge’s team primarily consisted of Anders StridJenny Sandlund and Edin Agic (Capital Markets), Victor Ericsson and Emelie Svanberg (Tax), Anna Ståhlklo (Commercial Agreements), Alexander Lindeberg (IP) and Rebecka Hansson (Employment Law).

Related

Vinge has advised Sertion AB in connection with the acquisition of Svensk Anläggning och Driftteknik AB

Through the acquisition, Sertion takes a further step in its development as a leading international infrastructure and installation group within complex HVAC systems, technical infrastructure, and industrial piping. Svensk Anläggning och Driftteknik AB specializes in certified welding and installation of industrial piping.
February 10, 2026

Vinge advises Mirova in connection with the acquisition of the Boarp, Dållebo and Fågelås wind farms

Vinge has advised Mirova, a subsidiary of Natixis Investment Managers focusing on sustainable investments, in connection with the acquisition of the three Swedish onshore wind farms Boarp, Dållebo and Fågelås.
February 10, 2026

Vinge has advised Bridgepoint in its acquisition together with Polaris of a majority stake in PDSVISION, a global leader in digital engineering

Headquartered in Stockholm, PDSVISION operates across North America, Europe and Asia. The company delivers integrated software and services that support digital transformation in product development and manufacturing, helping customers improve productivity and accelerate the journey from concept to production. The company has built a subscription-led business with ~SEK 1.7 billion in revenues, characterised by longstanding customer relationships and strong organic growth.
February 10, 2026